Compare Gilead Sciences, Inc. (GILD) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs MasTec Inc — how do they compare? Gilead Sciences, Inc. trades at $135.56 (market cap $163.51B), while MasTec Inc trades at $339.22 (market cap $28.27B). The key difference: Gilead Sciences, Inc. is far larger — about 5.8× MasTec Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while MasTec Inc pays none. Which is the better fit depends on your goals.
| GILD | MTZ | |
|---|---|---|
Market Cap | $163.51B | $28.27B |
Sector | Health | Technology |
52-Week High | $155.80 | $437.51 |
52-Week Low | $108.22 | $172.51 |
Enterprise Value | $178.05B | $31.01B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
MasTec (MTZ) trades at $336.22, down 7.91% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.39, and holds a record $20.3 billion backlog. Recent news highlights a $1.65 billion acquisition of The Superior Group to expand AI data center infrastructure capabilities, signaling strategic growth in high-demand markets.
Outlook remains positive driven by infrastructure spending and AI demand, with a consensus price target of $481.77 implying 43% upside. Risks include integration challenges from acquisitions and elevated valuation multiples. Analyst consensus is strongly bullish with 89% buy ratings, supporting long-term growth prospects amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
